Vaxcyte, Inc. (NASDAQ:PCVX) Given Average Rating of “Moderate Buy” by Analysts

Vaxcyte, Inc. (NASDAQ:PCVX) has been given an average recommendation of “Moderate Buy” by the eight brokerages that are covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and six have issued a buy recommendation on the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $86.00.

Several analysts have issued reports on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Vaxcyte in a research note on Monday, July 6th. Wall Street Zen cut shares of Vaxcyte from a “sell” rating to a “strong sell” rating in a report on Tuesday, April 28th.

Insider Activity at Vaxcyte

In related news, CFO Andrew Guggenhime sold 10,000 shares of the business’s stock in a transaction dated Monday, July 6th. The stock was sold at an average price of $57.28, for a total transaction of $572,800.00. Following the completion of the transaction, the chief financial officer directly owned 104,395 shares in the company, valued at $5,979,745.60. The trade was a 8.74% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Grant Pickering sold 2,000 shares of the company’s stock in a transaction dated Friday, June 26th. The stock was sold at an average price of $55.23, for a total value of $110,460.00. Following the completion of the transaction, the chief executive officer owned 134,215 shares in the company, valued at $7,412,694.45. This represents a 1.47% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 75,448 shares of company stock valued at $4,091,197. Company insiders own 3.30% of the company’s stock.

Institutional Investors Weigh In On Vaxcyte

Several hedge funds have recently bought and sold shares of the stock. Smartleaf Asset Management LLC raised its position in shares of Vaxcyte by 156.2% during the 4th quarter. Smartleaf Asset Management LLC now owns 597 shares of the company’s stock valued at $27,000 after buying an additional 364 shares in the last quarter. Caitong International Asset Management Co. Ltd grew its position in Vaxcyte by 1,463.4% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 641 shares of the company’s stock worth $30,000 after acquiring an additional 600 shares in the last quarter. EverSource Wealth Advisors LLC grew its position in Vaxcyte by 33.0% in the fourth quarter. EverSource Wealth Advisors LLC now owns 741 shares of the company’s stock worth $34,000 after acquiring an additional 184 shares in the last quarter. Capital Advisors Ltd. LLC bought a new position in Vaxcyte in the first quarter valued at $58,000. Finally, Allworth Financial LP increased its stake in Vaxcyte by 148.9% in the third quarter. Allworth Financial LP now owns 1,222 shares of the company’s stock valued at $44,000 after acquiring an additional 731 shares during the last quarter. 96.78% of the stock is currently owned by institutional investors.

Vaxcyte Stock Down 1.4%

NASDAQ PCVX opened at $56.21 on Friday. The company has a market cap of $8.12 billion, a PE ratio of -8.17 and a beta of 1.22. Vaxcyte has a 52 week low of $29.08 and a 52 week high of $65.00. The firm’s 50-day simple moving average is $52.19 and its two-hundred day simple moving average is $54.09.

Vaxcyte (NASDAQ:PCVX) last released its quarterly earnings data on Wednesday, May 6th. The company reported ($2.30) EPS for the quarter, missing analysts’ consensus estimates of ($1.74) by ($0.56). During the same quarter in the prior year, the company posted ($1.04) EPS. As a group, equities research analysts anticipate that Vaxcyte will post -7.91 EPS for the current year.

Vaxcyte Company Profile

Vaxcyte, Inc (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing a new generation of preventive vaccines aimed at combating serious bacterial diseases. Headquartered in San Carlos, California, Vaxcyte leverages proprietary conjugation technologies to design and manufacture multivalent vaccines targeting pathogens for which there remain significant unmet medical needs. The company’s platform is intended to streamline the production of conjugate vaccines by improving antigen presentation and broadening strain coverage compared with conventional approaches.

Vaxcyte’s lead candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine designed to protect against 24 serotypes of Streptococcus pneumoniae.